Selective retinoids and rexinoids in cancer therapy and chemoprevention

Drug Discovery Today

Volumn 7, Issue 23, 2002, Pages 1165-1174

  Zusi, F Christopher ^a   Lorenzi, Matthew V ^a   Vivat Hannah, Valerie ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYL 7 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 3 PROPOXY 2 NAPHTHYL) 2,4,6 OCTATRIENOIC ACID; 4 (7,8,9,10 TETRAHYDRO 5,7,7,10,10 PENTAMETHYL 5H BENZO[E]NAPHTHO[2,3 B][1,4]DIAZEPIN 13 YL)BENZOIC ACID; 4 [(5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL)CARBOXAMIDO]BENZOIC ACID; 4 [2 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL) 1,3 DIOXOLAN 2 YL]BENZOIC ACID; 6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; AGN 193639; AGN 193835; AGN 193836; AGN 194301; AROTINOID; BEXAROTENE; BMS 185411; BMS 194753; BMS 195614; BMS 204493; BMS 228987; BMS 270394; BMS 276393; CD 666; FENRETINIDE; LE 540; MX 781; PA 452; PACLITAXEL; RETINOIC ACID RECEPTOR; RETINOID DERIVATIVE; RETINOL; SR 11254; TAMIBAROTENE; TAMOXIFEN; UNCLASSIFIED DRUG;

CANCER; CANCER CHEMOTHERAPY; CHEMOPROPHYLAXIS; CHONDROGENESIS; DRUG EFFECT; DRUG MECHANISM; HUMAN; HYPERTRIGLYCERIDEMIA; NONHUMAN; ONCOLOGY; REVIEW; SIDE EFFECT; TERATOGENICITY;

ANIMALS; GROWTH INHIBITORS; HUMANS; NEOPLASMS; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; RETINOIDS; TRANSCRIPTION FACTORS;

EID: 0036897019     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(02)02526-6     Document Type: Review

References (77)

1. Napoli J.L. Retinoic acid biosynthesis and metabolism. FASEB J. 10:1996;993-1001.
2. Hayden L.J. Metabolic conversion of retinol to retinoic acid mediates the biological responsiveness of human mammary epithelial cells to retinol. J. Cell Physiol. 186:2001;437-447.
3. Niederreither K., et al. Embryonic retinoic acid synthesis is essential for early mouse post-implantation development. Nat. Genet. 21:1999;444-448.
4. Wan Y.J.Y., et al. Hepatocyte-specific mutation establishes retinoid X receptor as a heterodimeric integrator of multiple physiological processes in the liver. Mol. Cell. Biol. 20:2000;4436-4444.
5. Imai T., et al. Selective ablation of retinoid X receptor in hepatocytes impairs their lifespan and regenerative capacity. Proc. Natl. Acad. Sci. U. S. A. 98:2001;4581-4586.
6. Love J.M., Gudas L.J. Vitamin A, differentiation and cancer. Curr. Opin. Cell Biol. 6:1994;825-831.
7. Vivat-Hannah V., et al. Synergistic cytotoxicity exhibited by combination treatment of selective retinoid ligands with taxol (Paclitaxel). Cancer Res. 61:2001;8703-8711.
8. Altucci L., et al. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat. Med. 7:2001;680-686.
9. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J. 10:1996;940-954.
10. Allenby G., et al. Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc. Natl. Acad. Sci. U. S. A. 90:1993;30-34.
11. Hu X., Lazar M.A. Transcriptional repression by nuclear receptors. Trends Endocrinol. Metab. 11:2000;6-10.
12. Germain P., et al. Co-regulator recruitment and the mechanism of retinoic acid receptor synergy. Nature. 415:2002;187-192.
13. Altucci L., Gronemeyer H. The promise of retinoids to fight against cancer. Nature Rev. Cancer. 1:2001;181-193.
14. Renaud J.P., et al. Crystal structure of the RAR-γ ligand binding domain bound to all-trans retinoic acid. Nature. 378:1995;681-689.
15. Shang Y., et al. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell. 103:2000;843-852.
16. Sharma D., Fondell J.D. Temporal formation of distinct thyroid hormone receptor coactivator complexes in HeLa cells. Mol. Endocrinol. 14:2000;2001-2009.
17. Rachez C., Freedman L.P. Mediator complexes and transcription. Curr. Opin. Cell Biol. 13:2001;274-280.
18. Benoit G., et al. RAR-independent RXR signaling induces t(15;17) leukemia cell maturation. EMBO J. 18:1999;7011-7018.
19. Venepally P., et al. Analysis of homo- and heterodimerization of retinoid receptors in solution. Arch. Biochem. Biophys. 343:1997;234-242.
20. Chen Z.P., et al. Ligand- and DNA-induced dissociation of RXRtetramers. J. Mol. Biol. 275:1998;55-65.
21. Kastner P., et al. Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life. Cell. 83:1995;859-869.
22. Arafa H.M.M., et al. Selective agonists of retinoic acid receptors: comparative toxicokinetics and embryonic exposure. Arch. Toxicol. 73:2000;547-556.
23. Vuligonda V., et al. A new class of RAR subtype selective retinoids: correlation of pharmacological effects with receptor activity. Bioorg. Med. Chem. 7:1999;263-270.
24. Standeven A.M., et al. Retinoid-induced hypertriglyceridemia in rats is mediated by retinoic acid receptors. Fundam. Appl. Toxicol. 33:1996;264-271.
25. Sun S.Y., Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit. Rev. Oncol. Hematol. 41:2002;41-55.
26. Widschwendter M., et al. Methylation and silencing of the retinoic acid receptor-β2 gene in breast cancer. J. Natl. Cancer Inst. 92:2000;826-832.
27. Sirchia S.M., et al. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor β2 promoter in breast cancer cells. Oncogene. 19:2000;1556-1563.
28. Di Croce L., et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science. 295:2002;1079-1082.
29. Sirchia S.M., et al. Endogenous reactivation of the RARβ2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res. 62:2002;2455-2461.
30. Faria T.N., et al. The targeted disruption of both alleles of RARβ2 in F9 cells results in the loss of retinoic acid-associated growth arrest. J.Biol. Chem. 274:1999;26783-26788.
31. Seewaldt V.L., et al. Expression of retinoic acid receptor β mediates retinoic-induced growth arrest and apoptosis in breast cancer cells. Cell Growth Differ. 6:1995;1077-1088.
32. Sun S.Y., et al. Evidence that retinoic acid receptor β induction by retinoids is important for tumor cell growth inhibition. J. Biol. Chem. 275:2000;17149-17153.
33. Geisen C., et al. Growth inhibition of cervical cancer cells by the human retinoic acid receptor β gene. Int. J. Cancer. 85:2000;289-295.
34. Houle B., et al. Tumor-suppressive effect of the retinoic acid receptor β in human epidermoid lung cancer cells. Proc. Natl. Acad. Sci. U. S. A. 90:1993;958-989.
35. Dawson M.I., Zhang X. Discovery and design of retinoic acid receptor and retinoid X receptor class- and subtype-selective synthetic analogs of all-trans-retinoic acid and 9-cis-retinoic acid. Curr.Med. Chem. 9:2002;623-637.
36. Kagechika H. Novel synthetic retinoids and separation of the pleiotropic retinoidal activities. Curr. Med. Chem. 9:2002;591-608.
37. Nagpal S., Chandraratna R. Recent developments in receptor-selective retinoids. Curr. Pharm. Design. 6:2000;919-931.
38. Klaholz B.P., et al. Enantiomer discrimination illustrated by high-resolution crystal structures of the human nuclear receptor hRARγ Proc. Natl. Acad. Sci. U. S. A. 97:2000;6322-6327.
39. Klaholz B.P., et al. Structural basis for isotype selectivity of the human retinoic acid nuclear receptor. J. Mol. Biol. 302:2000;155-170.
40. Bourguet W., et al. Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol. Cell. 5:2000;289-298.
41. Bourguet W., et al. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α Nature. 375:1995;377-382.
42. Egea P.F., et al. Crystal structure of the human RXRα ligand-binding domain bound to its natural ligand: 9-cis-retinoic acid. EMBO J. 19:2000;2592-2601.
43. Gehin M., et al. Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists. Chem. Biol. 6:1999;519-529.
44. Ostrowski J., et al. Serine 232 and methionine 272 define the ligand binding pocket in retinoic acid receptor subtypes. J. Biol. Chem. 273:1998;3490-3495.
45. Ostrowski J., et al. The N-terminal portion of domain E of retinoic acid receptors α and β is essential for the recognition of retinoic acid and various analogs. Proc. Natl. Acad. Sci. U. S. A. 92:1995;1812-1816.
46. Kikuchi K., et al. Syntheses and structure-activity relationships of 5,6,7,8-tetrahydro-5,5,8,8-tetra-methyl-2-quinoxaline derivatives with retinoic acid receptor α agonist activity. J. Med. Chem. 43:2000;409-419.
47. Teng M., et al. Identification of a retinoic acid receptor α subtype specific agonist. J. Med. Chem. 39:1996;3035-3038.
48. Kagechika H., et al. Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity. J. Med. Chem. 31:1988;2182-2192.
49. Zusi, F.C. et al. (1998) Preparation of 5-substituted 1,1,3,3-tetramethyl-2-ketoindanes as Retinoid-like Compounds. World Patent Application # 98-47,861.
50. Toriumi Y., et al. Crystallographic studies on retinoidal-active and -inactive aromatic anilides. J. Org. Chem. 55:1990;259-263.
51. Bernard B.A., et al. Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor γ Biochem. Biophys. Res. Commun. 186:1992;977-983.
52. Charpentier B., et al. Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes. J. Med. Chem. 38:1995;4993-5006.
53. Johnson A.T., et al. Identification of retinoic acid receptor β subtype specific agonists. J. Med. Chem. 39:1996;5027-5030.
54. Chen J.Y., et al. RAR-specific agonists/antagonists which dissociate trans-activation and AP1 transrepression inhibit anchorage-independent cell proliferation. EMBO J. 14:1995;1187-1197.
55. Teng M., et al. Identification of highly potent retinoic acid receptor α-selective antagonists. J. Med. Chem. 40:1997;2445-2451.
56. Li Y., et al. Identification of a novel class of retinoic acid receptor β-selective retinoid antagonists and their inhibitory effects on AP-1 activity and retinoic acid-induced apoptosis in human breast cancer cells. J. Biol. Chem. 274:1999;15360-15366.
57. Mata de Urquiza A., et al. Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science. 290:2000;2140-2144.
58. Boehm M.F., et al. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J. Med. Chem. 37:1994;2930-2941.
59. Farmer L.J., et al. Synthesis and structure-activity relationships of potent retinoid X receptor ligands. Bioorg. Med. Chem. Lett. 7:1997;2393-2398.
60. Farmer L.J., et al. Synthesis and structure-activity relationships of potent conformationally restricted retinoid X receptor ligands. Bioorg. Med. Chem. Lett. 7:1997;2747-2752.
61. Lala D.S., et al. Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature. 383:1996;450-453.
62. Takahashi B., et al. Novel retinoid X receptor antagonists: specific inhibition of retinoid synergism in RXR-RAR heterodimer actions. J. Med. Chem. 45:2002;3327-3330.
63. Takeshita A., et al. Successful treatment of relapse of acute promyelocytic leukemia with a new synthetic retinoid, Am80. Ann. Intern. Med. 124:1996;893-896.
64. Takeuchi M., et al. Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am-80. Leuk. Lymphoma. 31:1998;441-451.
65. Ferrara F.F., et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res. 61:2001;2-7.
66. Fitzgerald P., et al. Retinoic acid receptor α expression correlates with retinoid-induced growth inhibition of human breast cancer cells regardless of estrogen receptor status. Cancer Res. 57:1997;2642-2650.
67. Suzuki S., et al. Implication of mitochondria-derived reactive oxygen species, cytochrome C and caspase-3 in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. Oncogene. 18:1999;6380-6387.
68. Sun S.Y., et al. Induction of Fas expression and augmentation of Fas/Fas ligand-mediated apoptotis by the synthetic retinoid CD437 in human lung cancer cells. Cancer Res. 60:2000;6537-6543.
69. Sun S.Y., et al. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid (CD437) through upregulation of TRAIL receptors in human lung cancer cells. Cancer Res. 60:2000;7149-7155.
70. Formelli F., et al. Bioactivities of N-(4-hydroxyphenyl) retinamide and retinoyl β- glucuronide. FASEB J. 10:1996;1014-1024.
71. Gottardis M.M., et al. Chemoprevention of mammary carcinoma by LGD1069 (targretin): an RXR selective ligand. Cancer Res. 56:1996;5566-5570.
72. Bischoff E.D., et al. Beyond Tamoxifen: the RXR receptor-selective ligand LGD1069 (targretin) causes complete regression of mammary carcinoma. Cancer Res. 58:1998;479-484.
73. Bischoff E.D., et al. Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure. J.Natl. Cancer Inst. 91:1999;2118-2123.
74. Wu K., et al. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol. Biomarkers Prev. 11:2002;467-474.
75. Agarwal V.R., et al. Induction of adipocyte-specific gene expression is correlated with mammary tumor regression by the retinoid X receptor-ligand LGD1069 (Targretin). Cancer Res. 60:2000;6033-6038.
76. Duvic M., et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J. Clin. Oncol. 19:2001;2456-2471.
77. Miller V.A., et al. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J. Clin. Oncol. 15:1997;790-795.